Trabeculectomy with double low dose of mitomycin C – two years of follow-up by Errico, Donato et al.
© 2011 Errico et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2011:5 1679–1686
Clinical Ophthalmology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1679
REVIEW
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S25611
Trabeculectomy with double low dose  
of mitomycin C – two years of follow-up
Donato Errico1
Francesca Scrimieri1
Roberta Riccardi1
Romolo Fedeli1
Giancarlo Iarossi2
1Opthalmology Unit, Glaucoma 
Service, Azienda Ospedaliera, 
Cardinale G Panìco, Tricase (Le), 
Italy; 2Department of Opthalmology, 
Ospedale Pediatrico Bambino Gesù, 
Rome, Italy
Correspondence: Donato Errico 
Piazza Cappuccini, 24  
73039 Tricase – Lecce, Italy 
Tel +390 8337 73111 
Email donato.errico@tiscali.it
Purpose: To evaluate the efficacy and the safety of a surgical technique in which classic 
  trabeculectomy ab externo is performed with a double application of low-dose mitomycin C 
(MMC) in uncontrolled open-angle glaucoma (OAG) patients.
Method: A consecutive series of 43 white patients (43 eyes) with uncontrolled primary OAG 
underwent trabeculectomy surgery. A double application of MMC (0.1%) was performed: the 
first under the Tenon’s capsule for 3 minutes, and the second below the scleral flap for 1 or 
2 minutes, according to the risk factors. Complete success was defined as intraocular pressure 
(IOP) ,14 mmHg without any additional glaucoma surgery or medication. Qualified success 
was defined as IOP ,14 mmHg with additional needling revision.
Results: Mean preoperative IOP was 29.9 mmHg (SD 3.8) for all eyes evaluated. At 1 day 
postoperative, mean IOP was 6.7 mmHg (SD 1.26). At the end of the first 2 weeks postoperative, 
mean IOP was 8.6 mmHg (SD 1.7), at 12 months mean IOP was 11.3 mmHg (SD 1.4; 
P , 0.0001) and at 24 months mean IOP was 11.4 mmHg (SD 1.5; P , 0.0001). At 3 months, 
two eyes (5.4%) underwent needling of the bleb for cystic blebs formation.
Conclusion: In this study we presented the results after 2 years of follow-up of OAG undergoing 
trabeculectomy with dual administration of MMC (0.1 mg/mL). After 24 months, complete 
success was achieved in 93% of patients and a qualified success in 100% of patients.
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Introduction
Glaucoma is an ocular disorder characterized by visual field defects and optic nerve 
head (ONH) damage mainly due to increased intraocular pressure (IOP). Other risk 
factors such as ocular blood flow, optic disk appearance, and ganglion cell degeneration 
are involved in the pathogenesis, but to date, lowering the IOP represents the most 
important clinically significant parameter to prevent the progression of the disease.1,2 
Indeed, the only accepted treatment for glaucoma is reduction in the IOP, and in many 
cases, optimal IOP regulation cannot be achieved without surgery.
Trabeculectomy is the gold standard filtrating surgical treatment for medically 
uncontrolled glaucoma disease since its introduction by Cairns in 1968.3 The   success 
of filtrating surgery depends on the healing of the fistula and surrounding tissue, 
as the fistula can be blocked by a rapidly progressing scar soon after the filtration 
surgery. Therefore, antiproliferative agents have long been used in conjunction with 
trabeculectomy in order to inhibit subconjunctival scarring via decreasing fibroblastic 
activity and modulating wound healing at the bleb site.4Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Mitomycin C (MMC) is one of the most commonly 
used antiproliferative agents, introduced at the beginning 
of the 1980s. It is an antineoplastic antibiotic agent isolated 
from the filtrate fermentation of Streptomyces caespitosus, 
and has been shown to suppress fibroblastic activity and 
  consequently to inhibit wound healing.5 The advantages of its 
intraoperative use are a reduction of corneal complications, 
a greater lowering of intraocular pressure, and the elimination 
of postoperative drugs.6,7 However, complications associated 
with the use of MMC are the formation of thin walled and 
avascular blebs and extreme hypotony, with or without 
maculopathy. Toxic effects and complications secondary 
to use of MMC are strictly dependent on dose and time 
exposure.8–10 The application method of antimetabolite agents 
during trabeculectomy surgery can affect the drainage bleb 
morphology and its long-term survival.11
Some surgeons prefer to place sponges soaked in 
antimetabolite on the subconjunctival space or below the 
Tenon’s layer,12,13 or to inject antimetabolite into Tenon’s 
layer14 prior to scleral flap dissection, while others prefer to 
place the sponges under the scleral flap itself.15
In this article, we describe a technique in which double 
application of low-dose MMC (0.1 mg/mL) is performed; 
the first dose is injected into Tenon’s layer and the second is 
administered by placing a soaked sponge under the dissected 
scleral flap.
Material and methods
This is a retrospective case controlled study. The research 
followed the tenets of the Declaration of Helsinki. The study 
was approved by the ethics committee of the Cardinal G 
Panìco Hospital of Tricase.
All the patients were admitted to Cardinal G Panìco 
Hospital of Tricase for examination at the glaucoma unit. 
A consecutive series of 43 Caucasian patients (43 eyes), 
28 men and 15 women, with uncontrolled open-angle 
glaucoma (OAG), were recruited for this study between 
June 2008 and February 2009. Their mean age was 59.5 
years (SD 15.7). Of the 43 patients, 25 were pseudophakic 
and 18 phakic. Pseudophakic patients had been exposed to 
phacoemulsification with   temporal access at least 3 months 
before trabeculectomy.
Patients were compared with 16 controls who   underwent 
trabeculectomy with a single dose of MMC 0.2 mg/mL under 
the scleral flap for 3 minutes in the same period.   Controls 
were seven pseudophakic and nine phakic with mean 
  preoperative IOP of 27.8 mmHg (SD 2.9). The mean age of 
controls was 62.7 years (SD 16.4).
Patients and controls were defined as having primary OAG 
(POAG) or secondary glaucoma (pigmentary,   exfoliative) if 
they had an abnormal visual field (as described below), and/or 
abnormal ONH/retinal nerve fibre layer (RNFL) identified 
by using a Volk +90 lens (Volk Optical, Inc, Mentor, OH), 
open angle by gonioscopy (Volk 2 in 1 handle gonio-lens 
(Volk Optical, Inc), and no clinically apparent secondary 
cause for their glaucoma.
The abnormal ONH and RNFL classifications were based 
on the presence of an optic rim notch or diffuse/generalized 
loss of optic rim tissue, vertical cup/disk diameter ratio 
asymmetry unexplained by side differences in optic disk 
size, disk hemorrhage, or a localized defect within the RNFL. 
The visual field testing was assessed with a Humphrey Field 
Analyzer (HFA, program 24-2, SITA standard, Humphrey 
Instruments, Munich, Germany). Patients were classified as 
having an abnormal visual field if on at least three consecutive 
tests they had a pattern deviation map with at least one of 
the following defects: (a) three adjacent points depressed by 
5 dB with one of the points down by at least 10 dB; (b) two 
adjacent points down by 10 dB; (c) a 10 dB difference across 
the nasal horizontal meridian in two adjacent points.
None of the points could be edge points except imme-
diately above or below the nasal horizontal meridian. Only 
reliable fields were used as determined by the reliability 
parameters (false positive responses and false negative 
responses ,30%, and fixation losses ,10%).16
Inclusion criteria were primary or secondary OAG 
patients under maximal tolerable antiglaucomatous therapy 
and with uncontrolled IOP (IOP .22 mmHg) and evident 
signs of deterioration of the visual field recorded in at least 
two consecutive examinations.16
Prior to surgical procedure, all patients underwent a 
  baseline examination including: measurement of best cor-
rected visual acuity; visual field examination (24-2, HFA); 
biomicroscopy, gonioscopy (Volk 2 in 1 handle gonio-lens, 
[Volk Optical, Inc], fundus examination (stereoscopic retinal 
view using Volk +90 diopters lens), and Goldmann appla-
nation tonometry (model AT 900; Goldmann Applanation 
Tonometer, HaaghStreit-Berne, Mason, OH).
Patients’ and controls’ data are reported in Table 1. 
Informed consent was obtained from each patient. All 
surgical procedures were performed by a single surgeon 
(Donato Errico).
Surgical method
A standardized surgical technique was used throughout the 
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treatment arms. The operation was performed under monitored 
anesthesia care using a peribulbar block; a 6-0 silk stay suture 
(B Braun Aesculap, Tuttlingen, Germany) was placed in the 
superior cornea and the eye inferiorly moved. A 30 gauge 
needle was passed through the conjunctiva (at 7 mm from 
limbus) and it was advanced laterally in Tenon’s capsule, 
creating a bubble (Figure 1); the wound bed was treated with 
MMC to prevent spread over the future site of the conjunctival 
wound. The concentration of MMC used was 0.1 mg/mL. After 
3 minutes, the perilimbal conjunctiva was opened 5–7 mm and 
saline solution was injected into Tenon’s capsule. The process 
was repeated three times, until a total of 10 mL of balanced 
saline solution was used. The exposed sclera under the con-
junctival flap was cleaned with gentle bipolar diathermy.
A scleral flap (4 × 3 mm) was created first by cutting an 
horizontal incision parallel to the limbus using a precali-
brate blade of 250 µm (BD, Waltham, MA), then dissecting 
a partial thickness scleral pocket by crescent knife angled 
bevel up (Alcon Ophthalmic, Fort Worth, TX), and finally 
cutting the two side incisions.
A 4 × 4 mm piece of sponge soaked in MMC (0.1 mg/mL) 
was placed under the dissected scleral flap (Figure 2). 
After an exposure time of 1–2 minutes (varied according to 
the risk factors) the sponge was removed and the area was irri-
gated with 20 mL of balanced saline solution. The risk factors 
taken into account were as follows (Table 2): preoperative IOP, 
more than 3 years of topical therapy for glaucoma, number 
of drugs employed, history of argon laser trabeculoplasty 
(ALT), and age. MMC was applied under the scleral flap for 
1 minute in case of two or fewer risk factors (23 eyes), and 
2 minutes in case of 3 or more risk factors (20 eyes).
A paracentesis was created using a 15° slit knife (Peasalls 
Ltd, Taunton, UK), followed by injection of carbacolo solu-
tion (Farmigea, Pisa, Italy) and viscoelastic solution (Healon 
GV Pharmacia, Uppsala, Sweden) in the anterior chamber.
The 2.85-mm blade (Peasalls Limited) was then used to 
enter the anterior chamber and create sclerotomy. A 1.5-mm 
diameter hemispherical block of corneal trabecular tissue 
was excised using a trabeculectomy punch (E Janach, Como, 
Italy) beneath the scleral flap.
An iridotomy was performed in all cases before the 
closure of the scleral flap with two 10-0 nylon interrupted 
sutures (Sharepoint Surgical Specialities Corporation, 
Reading, PA) (one at each corner, the knots of which were 
Table 1 Patient parameters – demography
Parameter Patient 
n (%)
Controls 
n (%)
Sex 
  Male 
  Female
 
28 (65%) 
15 (35%)
 
12 (75%) 
4 (25%)
Etiology of glaucoma 
  POAG 
  Exfoliative 
  Pigmentary
 
22 (51%) 
19 (44%) 
2 (5%)
 
10 (62.5%) 
6 (37.5%) 
–
Abbreviation: POAG, primary open angle glaucoma.
Figure 1 0.1 mg/mL mitomycin bubble inside Tenon’s capsule.
Table 2 Risk factors for surgery
High Low
IOP (mmHg)* .30 ,30
Age (years) ,46 .46
No of drugs 3 #2
Time of therapy (years) .3 ,3
ALT + -
Note: *With max tolerable therapy.
Abbreviations: IOP, intraocular pressure; ALT, argon laser trabeculoplasty.
Figure 2 4 × 4 mm piece of sponge soaked in mitomycin C (0.1 mg/mL or 0.2 mg/mL) 
under dissected scleral flap.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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buried within the sclera), and one releasable suture (centrally 
on the posterior lip of the flap).
The conjunctiva was closed using 8-0 Safil quick 
interrupted sutures (B Braun Aesculap, Tuttlingen, Germany) 
(Figure 3).
Postoperatively, a topical fixed combination of betameta-
sone and chloramphenicol was instilled four times daily for 
1 month and cyclopentolate 1% was instilled two times daily 
for 2 weeks.
Follow up
Postoperative data were collected daily during the first week, 
then at 2 weeks, and later at 1, 3, 6, 12, and 24 months. 
A routine ophthalmic examination was performed at each 
follow-up by evaluating visual acuity, IOP, anterior chamber 
depth, and bleb appearance.
Removal of releasable sutures and digital compression 
was done within the first 2 weeks as appropriate (sutures 
are usually removed at 2 weeks postoperative, but can be 
released earlier if the IOP raises to 19–20 mmHg. Needling 
is only performed in case of Tenonian cyst).
Complete success was defined as IOP ,14 mmHg with-
out any additional glaucoma surgery or medication, whereas 
qualified success was defined as IOP ,14 mmHg with addi-
tional needling revision. We chose a IOP level of 14 mmHg 
as the target because eyes with IOP less than 14 mmHg are 
usually believed to be at a safe level of pressure.17
For bleb description, the Indiana Bleb Appearance Grad-
ing Scale (IBAGS) classification was used.18   Statistical analy-
sis was performed using MedCalc® (v 11.3.3.0;   MedCalc 
Software, Mariakerke, Belgium). Conversion of Snellen 
acuity to the logarithm of the minimum angle of   resolution 
values was performed. One-way analysis of variance 
(ANOVA) was used to calculate the difference in pre-IOP 
and final IOP, ∆IOP, and ∆ visual acuity (VA) in patients 
with different glaucoma diagnoses. P values were calculated 
using paired sample t-tests for preoperative and postopera-
tive values. The one sample t-test was used to evaluate the 
significance of change in each parameter.
Results
All 43 patients (43 eyes), completed the study. IOP data in 
patients and controls are reported in Table 3.
At the end of the first postoperative 2 weeks, mean 
IOP was 8.6 mmHg (SD 1.7); at 12 months mean IOP was 
11.3 mmHg (SD 1.4; P , 0.0001); and at 24 months mean 
IOP was 11.4 mmHg (SD 1.5; P , 0.0001) (Figure 4A).
In controls at 2 weeks mean IOP was 8.9 mmHg 
(SD 1.9); at 12 months mean IOP was 14.8 mmHg (SD 2.9); 
and at 24 months mean IOP was 15.5 mmHg (SD 3.2) 
(Figure 4B).
In the patients group, at 24 months postoperative, the 
complete success rate, defined as IOP ,14 mmHg with-
out medication was 93%. Qualified success, defined as 
IOP ,14 mmHg with additional needling revision, was 
achieved in 100% of eyes. In the controls group, at 24 months 
of follow-up, the complete success rate was 67% and qualified 
success was achieved with 79% of eyes.
The bleb in 79% (34 eyes) of the patients appeared to 
extend laterally and posteriorly (29 eyes E2, five eyes E1), 
medium vascularity (V3) without cysts (Figure 5). In 
21% of patients (nine eyes) blebs were less extensive 
(E 1–2), avascular (V1) with cysts (Figure 6). All blebs were 
moderately high (H2), no corkscrew vessels were observed 
(Table 4).
Hypotony was defined as IOP readings of ,7 mmHg 
obtained on 2 separate days up to 2 weeks postoperative.
The most frequent early postoperative complications 
during the first 2 weeks after surgery were shallow anterior 
Figure 3 Eye appearance after surgery; releasable suture is visible.
Table 3 Intraocular pressure data in patients and controls
Follow-up MMC 0.1 two  
administrations 
IOP mmHg (SD)
MMC 0.2 single 
administration 
IOP mmHg (SD)
Preoperative 29.9 (3.8) 27.8 (2.9)
2 weeks 8.6 (1.7) 8.9 (1.9)
1 month 10.2 (2.4) 11.1 (2.5)
6 months 10.9 (1.9) 12.4 (2.1)
1 year 11.3 (1.4) 14.8 (2.9)
2 years 11.4 (1.5) 15.5 (3.2)
Abbreviations: MMC, mitomycin C; IOP, intraocular pressure.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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during the follow-up period. In all eyes, the releasable 
sutures were removed during the first 2 weeks of follow-up. 
At 3 months, three eyes (7%) underwent needling of the bleb 
for cystic formation.
Scleral ectasia adjacent to the site of sclerectomy 
was not observed during the follow-up period of 2 years. 
Neither persistent nor late bleb leakage nor severe compli-
cations, such as bleb infection, endophthalmitis or choroi-
dal hemorrhages, were seen in this series.
Best correct visual acuity did not change after trabeculec-
tomy (P = 0.56).
Discussion
The aim of trabeculectomy surgery is to produce a 
long-functioning drainage fistula, with minimal risk 
of complications.
The use of MMC to modulate healing allows lower IOPs 
to be obtained, but it can cause severe complications such 
as thin or ischemic blebs, which are associated with   leakage 
and increased risks of endophthalmitis and hypotonous 
maculopathy. Different application methods of MMC have 
been proposed to increase its efficiency while decreasing its 
toxic effects. Various studies have mainly focused on the 
exposure time of MMC during the surgery and the dosing 
scheme of the agent.4,9,12–14
The inhibitory effects of MMC on subconjunctival fibro-
blast proliferation in vitro have been shown to be dose and 
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Figure 4 Mean IOP evolution pre- and postoperative: (A) patients (B) controls.
Abbreviation: IOP, intraocular pressure.
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chamber (ten eyes, 21.7%, mainly in the first 3 days), 
hyphema (two eyes, 4.6%), and serous choroidal detach-
ments posterior to the equator (five eyes, 11.6%). None 
of the choroidal detachments required surgical drain-
age nor did phakic patients undergo cataract surgery 
Figure 5 Appearance of bleb without cysts (E2-V3-H2).
Table 4 Bleb classification using the Indiana Bleb Appearance 
Grading Scale – 200318
Height Extent Vascularity
1 2 3 4 0 1 2 3 1 2 3 4
Eyes (n) 5 38 3 11 29 9 34Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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time dependent.19 Previous authors reported the use of MMC 
concentration ranging from 0.1 mg/mL to 0.4 mg/mL.6,20 
Chen et al20 reported failure rates of 37.5% using an MMC 
concentration of 0.1 mg/mL, 21.9% using a concentration of 
0.2 mg/mL, and no failure using a concentration of 0.4 mg/mL. 
The success for an IOP target ,21 mmHg was 77.8%, (35/45 
eyes in high-risk groups). Kitazawa et al in a prospective, 
randomized study in glaucoma patients with poor surgical 
prognosis demonstrated that the success rate was 88% of 
treated eyes using a dose of the 0.4 mg/mL MMC.
Lee et al14 injected MMC into Tenon’s capsule; MMC 
concentrations were variable (0.2–0.5 mg/mL in accordance 
with risk factors) and the time of administration was 
5 minutes. Ninety-three eyes (86%) had an IOP , 21 mmHg; 
79 (73%) had an IOP ,16 mmHg; and 62 (57%) had an 
IOP ,14 mmHg without antiglaucoma medication at 
12 months.
Other studies in which MMC has been applied directly 
to the sclera with MMC-soaked sponges reported high suc-
cess rates. Beckers et al21 reported a rate of 83% of patients 
who achieved an IOP of 15 mmHg or less at 1 year, whereas 
Fontana et al22 had 84% of treated patients with an IOP of 
15 mmHg or less at 1 year, with an IOP reduction of at least 
25% with respect to preoperative values. In these studies, the 
concentration of MMC was 0.2 mg/mL (for 3 minutes) and 
0.3 mg/mL (for 1–3 minutes), respectively.
El Sayyad et al23 compared the results obtained with 
administration of MMC 0.3 mg/mL (for 3 minutes) under 
the conjunctival flap (group 1), scleral flap (group 2), and 
double application under the scleral flap and conjunctival 
flap (group 3).
Clinically detectable blebs that were moderately elevated 
with microcystic conjunctival changes and controlled IOP 
were noted in 17 of 22 eyes (77%) in group 1, 15 of 21 eyes 
(71%) in group 2, and 18 of 22 eyes (82%) in group 3 at 
1 year after surgery.
Chen et al20 reported hypotony in 16 of 47 eyes. Hypotony 
of 9 mmHg or less tended to occur more frequently at the 
higher concentrations of MMC used (0.2 and 0.4 mg/mL). 
Palmer6 using 0.2 mg/mL MMC reported one (3.8%) 
of 26 eyes having hypotony below 5 mmHg. These two 
clinical results reported hypotony rates of 3.8% using 
MMC concentrations of 0.2% mg/mL and 66.7% using a 
concentration of 0.4% mg/mL. The incidence of hypotony 
after trabeculectomy increased as a function of MMC 
concentration used during surgery.
When MMC was injected into Tenon’s capsula,14 hypotony 
was reported in 21.3% of cases. At 1 year of follow-up, 19.4% 
of patients showed evidence of cystic blebs and 4.6% had a 
Tenon’s cyst with an IOP .20 mmHg.
El Sayyad et al23 reported intraoperative complications, 
including conjunctival leaks, in one eye in groups 1 and 2, 
respectively, compared with two eyes in group 3. One eye in 
group 3 required conjunctival resuturing. Choroidal effusion, 
which required choroidal drainage, occurred in one eye 
in group 1. Hypotony (IOP #6 mmHg) was encountered 
in two eyes in group 1 and in one eye in groups 2 and 3, 
respectively.
In trabeculectomy, another important element to con-
sider is the extent and appearance of the bleb. Ideally, the 
bleb should be diffuse and mildly elevated, with normal 
vascularization.24
Önol et al,25 in a comparative study, reported major 
long-term success without increased surgical complication 
rates for MMC large-area application. The authors 
compared two groups of OAG patients undergoing 
trabeculectomy with MMC (0.2 mg/mL for 2 minutes) 
application with sponges size 4 × 4 mm (group 1, small-
area) and 5 × 5 mm (group 2, large-area). At the end of the 
second year, target IOP was achieved in 94.2% of cases in 
group 2 and 68.7% of cases in group 1 (P , 0.05). Mean 
IOP and additional antiglaucoma medication for the IOP 
control were less in group 2 than in group 1 (P , 0.05). 
These findings   suggest that large-area MMC application 
seems to be more advantageous than small-area MMC 
application in terms of achieving and maintaining target 
IOP in the long term.
Cordeiro et al26 observed thin and more diffuse blebs with 
large sponges whereas small and cystic blebs were noted after 
the use of small sponges. Histopathologic analysis showed a 
more significant cellular infiltration in small and cystic blebs 
in comparison with diffuse blebs. They proposed that this 
cellular infiltration derived from fibroblasts of healthy tissue 
surrounding the bleb area, and this cellular migration might 
contribute to the formation of these cystic blebs which were 
seen in the small-area MMC group.
The area of action of MMC is localized to the area of 
exposure. Applying the antimetabolites over a wide area is 
believed to reduce the risk of a cystic bleb forming as well 
as avoiding increased risks of premature failure caused by 
scarring around the drainage site.27
In this study we presented the results of a 2-year 
follow-up of OAG patients after trabeculectomy with dual 
administration of MMC (0.1 mg/mL). After 24 months, 
  complete success was achieved in 93% of patients and 
qualified success in 100% of patients.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Our data were consistent with previous studies15 where 
the concentration of MMC was 0.4 mg/mL and higher, than 
those obtained with a concentration of 0.1–0.2 mg/mL. 
By comparing our data with those of group 3 in the El Sayyad23 
study, we observed a greater success rate (93% vs 82%) and 
a lower percentage of  postoperative complications. A   similar 
success rate (94.2%) was achieved by Önol et al25 after 
administration of MMC with concentration 0.2 mg/mL for 
2 minutes over a large area.
Hypotony in the present study was observed in 4.6% 
(two eyes). This percentage is higher than that reported in a 
previous study6 where the MMC at 0.2 mg/mL (3.8%) was 
administered under conjunctiva before dissection of the 
scleral flap, but lower than using a 0.4 mg/mL concentration 
of MMC (66.7%). Rate of hypotony was lower to that 
reported (21.3%) when MMC was administered intra-Tenon’s 
capsule.14 However, in the present study there was no late 
hypotony. Diffuse filtration was observed in cases with large-
area MMC application in the early postoperative period.
At 2 years follow-up, we recorded a 7% percentage of 
  cystic blebs, significantly lower compared to other   studies 
where cystic bleb percentage was 19.4%12 and 8.8%.25 
The scleral flap and Tenon’s capsule are also involved in 
the process of fibrosis after trabeculectomy. In accordance 
with previous reports from Lee14 and El Sayyad,23 we have 
standardized the technique of dual administration of MMC 
0.1 mg/mL for 4–5 minutes (varied according to the risk 
factors). The administration of MMC into Tenon’s layer at 
7 mm from the limbus allows the formation of a posteriorly 
extended and moderately high bleb. The anterior margin 
of the bubble formed was approximately located at the 
posterior edge of the scleral flaps. Administration of MMC 
under the scleral flap permitted the extension of treatment 
with MMC over a wider area. The two-step administration 
of single doses of MMC at low percentage (0.1 mg/mL) 
covered a large area for a short time (the first for 3 minutes, 
the second for 1–2 minutes). This prevented the same tissue 
from coming in contact with the MMC twice. The applica-
tion of MMC at low doses significantly reduced postopera-
tive complications.
In conclusion, at 24 months after surgery the blebs were 
widespread, thick-walled, moderately high, and posteriorly 
extended showing an excellent anatomical and functional 
outcome after the procedure.
Disclosure
The authors have no proprietary or commercial interests 
in any materials discussed in the article. The study was 
  conducted without the support of external grants and the 
property of the work is exclusively the authors’.
References
  1.  Katz LJ, Spaeth GL, Cantor LB, Poryzees EM, Steinmann WC. 
  Reversible optic disk cupping and visual field improvement in adults 
with glaucoma. Am J Ophthalmol. 1989;107:485–492.
  2.  O’Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure 
and the rate of visual field loss in chronic open-angle glaucoma. Am J 
Ophthalmol. 1991;111:491–500.
  3.  Cairns JE. Trabeculectomy – a preliminary report of a new method. Am 
J Ophthalmol. 1968;66:673–679.
  4.  Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma 
surgery. Surv Ophthalmol. 2003;48:314–346.
  5.  Singh G, Wilson MR, Foster CS. Mitomycin drops a treatment for 
pterygium. Ophthalmology.1988;95:813–821.
  6.  Palmer SS. Mitomycin as adjunct chemotherapy with trabeculectomy. 
Ophthalmology. 1991;98:317–321.
  7.  Kitazawa Y, Kawasw K, Matsushita H, Minobe M. Trabeculectomy with 
mitomycin. A comparative study with fluorouracil. Arch Ophthalmol. 
1991;109:1693–1698.
  8.  Membrey WL, Bunce C, Poinoosawmy DP, Fitzke FW, Hitchings RA. 
Glaucoma surgery with or without adjunctive antiproliferatives in 
normal tension glaucoma: 2. Visual field progression. Br J Ophthalmol. 
2001;85:696–701.
  9.  Maquet JA, Dios E, Aragón J, Bailez C, Ussa F, Laguna N. Protocol 
for mitomycin C use in glaucoma surgery. Acta Ophthalmol Scand. 
2005;83:196–200.
  10.  Jampel HD. Effect of brief exposure to mitomycin C on viability 
and proliferation of cultured human Tenon’s capsule fibroblast. 
  Ophthalmology. 1992;99:1471–1476.
  11.  You YA, Gu YS, Fang CT, Ma XQ. Long-term effects of simultaneous 
subconjunctival and subscleral Mitomycin-C application in repeat 
trabeculectomy. J Glaucoma. 2002;11:110–118.
  12.  Skuta GL, Beeson CC, Higginbotham EJ, et al. Intra-operative 
mitomycin versus postoperative 5Fluorouracil in high-risk glaucoma 
filtering surgery. Ophthalmology. 1992;99:438–444.
  13.  Sisto D, Vetrugno M, Trabucco T, Cantatore F, Ruggeri G, 
  Sborgia C. The role of antimetabolites in filtration surgery for neovas-
cular   glaucoma: intermediate-term follow-up. Acta Ophthalmol Scand. 
2007;85:267–271.
  14.  Lee E, Doyle E, Jenkins C. Trabeculectomy surgery augmented 
with intra-Tenon injection of mitomycin C. Acta Ophthalmol. 2008; 
86:866–870.
  15.  Beatty S, Potamitis T, Kheterpal S, O’Neill EC. Trabeculectomy 
augmented with Mitomycin-C application under the scleral flaps. Br J 
Ophthalmol. 1998;82:397–403.
  16.  Canadian Ophthalmological Society Glaucoma Clinical Practice 
Guideline Expert Committee; Canadian Ophthalmological Society. 
Canadian Ophthalmological Society evidence-based clinical practice 
guidelines for the management of glaucoma in the adult eye. Can J 
Ophthalmol. 2009;44 Suppl 1:S7–S93.
  17.  AGIS Investigators. The Advanced Glaucoma Intervention 
Study (AGIS): 7. The relationship between control of intraocular 
  pressure and visual field deterioraton. Am J Ophthalmol. 2000;130: 
429–440.
  18. Cantor LB, Mantravadi A, WuDunn D, et al. Morphologic 
  classification of filtering blebs after glaucoma filtration surgery: the 
Indiana Bleb Appearance Grading Scale. J Glaucoma. 2003;12(3): 
266–271.
  19.  Yamamoto T, Varani J, Soong HK, Lichter PR. Effects of 5-  fluorouracil 
and mitomycin C on cultured rabbit subconjuntival fibroblast. 
Ophthalmology. 1990;97:1204–1210.
  20.  Chen CW, Huang HT, Bair JS, Lee CC. Trabeculectomy with 
simultaneous topical application of mitomycin C in refractory glaucoma. 
J Ocul Pharmacol. 1990;6:175–182.Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1686
Errico et al
  21.  Beckers HJ, Kinders KC, Webers CA. Five-year results of trab-
eculectomy with Mitomycin-C. Graefes Arch Clin Exp Ophthalmol. 
2003;241:106–110.
  22.  Fontana H, Nouri-Mahdavi K, Lumba J, Ralli M, Caprioli J. 
Trabeculectomy with Mitomycin-C: outcomes and risk factors for failure 
in phakic open angle glaucoma. Ophthalmology. 2006;113:930–936.
  23.  El Sayyad F, Belmekki M, Helal M, Khalil M, El-Hamzawey H, 
Hisham M. Simultaneous subconjunctival and subscleral Mitomycin-C 
application in trabeculectomy. Ophthalmology. 2000;107:298–302.
  24.  Jones E, Clarke J, Khaw PT. Recent advances in trabeculectomy 
  technique. Curr Opin Ophthalmol. 2005;16:107–113.
  25.  Önol M, Aktas Z¸ Hasanreisoglu B. Enhancement of the success rate in 
trabeculectomy: large-area mitomycin-C application. Clin Experiment 
Ophthalmol. 2008;36:316–322.
  26.  Cordeiro MF, Constable PH, Alexander RA, Bhattacharya SS, Khaw PT. 
Effect of varying mitomycin-C treatment area in glaucoma filtration 
surgery in the rabbit. Invest Ophthalmol Vis Sci. 1997;38:1639–1646.
  27.  Wells AP, Cordeiro MF, Bunce C, Khaw PT. Cystic bleb formation 
and related complications in limbus-versus fornix-based conjunctival 
flaps in pediatric and young adult trabeculectomy with Mitomycin-C. 
Ophthalmology. 2003;110:2192–2197.